These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30699195)

  • 21. Correction: Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort.
    Gomides APM; de Albuquerque CP; Santos ABV; Amorim RBC; Bértolo MB; Júnior PL; Santos IA; Giorgi RDN; Sacilotto NC; Radominski SC; Borghi FM; Guimarães MFBR; Pinto MRDC; Resende GG; Bonfiglioli KR; Silva HCD; Sauma MFLDC; Sauma ML; de Medeiros JB; Pereira IA; de Castro GRW; Brenol CV; Xavier RM; da Mota LMH; Pinheiro GDRC
    PLoS One; 2019; 14(4):e0215198. PubMed ID: 30947308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correction: Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
    Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
    PLoS One; 2020; 15(4):e0231481. PubMed ID: 32240271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan.
    Takeuchi T; Ishida K; Shiraki K; Yoshiyasu T
    Mod Rheumatol; 2018 Jan; 28(1):48-57. PubMed ID: 28649878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study.
    Raknes G; Småbrekke L
    PLoS One; 2019; 14(10):e0223545. PubMed ID: 31574126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction: (In)Visible illness: A photovoice study of the lived experience of self-managing rheumatoid arthritis.
    Donnelly S; Wilson AG; Mannan H; Dix C; Whitehill L; Kroll T
    PLoS One; 2021; 16(4):e0250451. PubMed ID: 33852646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction: Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study.
    Choi S; Lee KH
    PLoS One; 2018; 13(6):e0199468. PubMed ID: 29912956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
    Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correction to Expression of Concern on: Functional Improvement of Regulatory T Cells from Rheumatoid Arthritis Subjects Induced by Capsular Polysaccharide Glucuronoxylomannogalactan.
    PLOS ONE Staff
    PLoS One; 2021; 16(3):e0249512. PubMed ID: 33780509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(6):e0179308. PubMed ID: 28582423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies.
    Ikeda K; Watanabe K; Hirai T; Tanji K; Miyashita T; Nakajima S; Uomori K; Morimoto S; Takamori K; Ogawa H; Takasaki Y; Sekigawa I
    Intern Med; 2017; 56(10):1147-1152. PubMed ID: 28502927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
    Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Singh JA; Cameron C; Noorbaloochi S; Cullis T; Tucker M; Christensen R; Ghogomu ET; Coyle D; Clifford T; Tugwell P; Wells GA
    Lancet; 2015 Jul; 386(9990):258-65. PubMed ID: 25975452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Suto T; Okura C; Takagishi K
    Mod Rheumatol; 2015 Jul; 25(4):534-9. PubMed ID: 25529033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.
    Hara M; Abe T; Sugawara S; Mizushima Y; Hoshi K; Irimajiri S; Hashimoto H; Yoshino S; Matsui N; Nobunaga M; Nakano S
    Mod Rheumatol; 2007; 17(1):1-9. PubMed ID: 17278015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [DMARDs (disease-modifying antirheumatic drugs)].
    Tanaka E; Yamanaka H
    Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
    Yoshioka Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Kanda H; Takagi H; Ito T; Kato T; Saito K; Funahashi K; Asai S; Takemoto T; Terabe K; Asai N; Ishiguro N; Kojima T
    Mod Rheumatol; 2016; 26(2):169-74. PubMed ID: 26140467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
    Ishiguro N; Yamamoto K; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Hara M;
    Mod Rheumatol; 2013 May; 23(3):430-9. PubMed ID: 22833377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus.
    Ishida K; Shiraki K; Yoshiyasu T
    Drugs R D; 2015 Dec; 15(4):307-17. PubMed ID: 26386566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction: Correlation of serum cartilage oligometric matrix protein (COMP) and interleukin-16 (IL-16) levels with disease severity in primary knee osteoarthritis: A pilot study in a Malaysian population.
    Das Gupta E; Ng WR; Wong SF; Bhurhanudeen AK; Yeap SS
    PLoS One; 2017; 12(12):e0190542. PubMed ID: 29281738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.